Skip to content

BridgeBio Pharma

US · BBIO #1254 by market cap Listed 2019
76.03 -2.15 -2.75%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:01

✦ Quant Ownership Signal how this is computed

Accumulating
  • The number of reporting institutions decreased by 2 in the most recent period (2026/Q4).
  • Total institutional ownership rose 0.6 percentage points.

Ownership vs. money flow

Aligned

Institutions added shares last reporting period, and the stock has seen net inflows in main-fund flow over the last 20 trading sessions - the two line up.

Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.

Institutional ownership

Held by institutions
100.89% +0.58pp
Institutions
578 -2
As of
2026/Q4 vs. prior period

Holder types

Mutual Fund60.30%
Hedge Fund25.61%
VC/PE Fund7.59%
Individual/Insider3.95%
Public Company3.16%
Private Company2.05%
Sovereign Wealth Fund0.87%
Government Pension Fund0.67%
Endowment Fund0.32%
Insurance Company0.23%

Top holders as of 2026-09-30

Farallon Capital Management, L.L.C. 7.31% · 14.25M sh
Janus Henderson Group plc 7.24% · 14.11M sh
BlackRock 5.33% · 10.39M sh
Viking Global Investors LP 5.03% · 9.79M sh
Wellington Management Group 4.86% · 9.46M sh
Vanguard Capital Management, LLC 4.64% · 9.04M sh
KKR & Co. Inc. 4.24% · 8.26M sh
Vanguard Portfolio Management, LLC 3.84% · 7.49M sh
Neil Kumar 2.61% · 5.09M sh
Two Sigma Investments, LP 2.42% · 4.72M sh
State Street Global Advisors 2.56% · 4.98M sh

Bar length is relative to the largest holder shown here, not to 100% of the company.

Insiders

50 filings tracked · 26 buys · 24 sells

NameRoleStake
Neil Kumar Chief Executive Officer 2.61%
Charles Homcy Co-Founder, Chairman of Pharmaceuticals & Lead Director 0.47%
Frank McCormick Co-Founder, Chairman of Oncology & Director 0.39%
Thomas Trimarchi CFO & President 0.16%
Ali Satvat Independent Director 0.08%
Maricel Apuli Chief Accounting Officer 0.06%
Brian Stephenson Former Chief Financial Officer 0.05%
James Momtazee Independent Director 0.05%
Andrew Lo Independent Director 0.03%
Wen-Chaun Lo Independent Director 0.03%
Douglas Dachille Independent Director 0.01%

Insider transactions most recent Form 4 filings

DateNameRoleTypeSharesPrice
2026-10-29 Maricel Apuli Chief Accounting Officer Automatic Disposition -2,000 $72.85
2026-09-16 Neil Kumar Chief Executive Officer Automatic Disposition -10,000 $69.01–69.57
2026-08-18 Neil Kumar Chief Executive Officer Automatic Disposition -44,980 $81.15–85.65
2026-08-17 Neil Kumar Chief Executive Officer Intent to Sell (Form 144) -34,980 $79.89
2026-08-16 Randal Scott Former Independent Director Intent to Sell (Form 144) -21,501 $79.86
2026-08-15 Neil Kumar Chief Executive Officer Derivative Exercise and Sale -36,237 $79.86
2026-08-15 Neil Kumar Chief Executive Officer Derivative Exercise and Retained +34,980 --
2026-08-15 Thomas Trimarchi CFO & President Sale to Issuer -22,781 $79.86
2026-08-15 Maricel Apuli Chief Accounting Officer Sale to Issuer -4,714 $79.86
2026-07-29 Maricel Apuli Chief Accounting Officer Automatic Disposition -2,000 $80.06
2026-07-08 Jennifer Cook Independent Director Derivative Exercise and Sale -148,589 $8.45–90.00
2026-07-08 Andrea Ellis Independent Director Derivative Exercise and Sale -17,167 $16.75–84.00
2026-06-23 Randal Scott Former Independent Director Intent to Sell (Form 144) -2,196 $68.63
2026-06-23 Jennifer Cook Independent Director Derivative Exercise and Sale -37,167 $8.45–70.00
2026-06-22 Jennifer Cook Independent Director Automatic Disposition -2,196 $68.57
2026-06-22 Hannah Valantine Independent Director Automatic Disposition -2,196 $68.57
2026-06-21 Charles Homcy Co-Founder, Chairman of Pharmaceuticals & Lead Director Other Acquisition +3,990 --
2026-06-21 Charles Homcy Co-Founder, Chairman of Pharmaceuticals & Lead Director Other Derivative Acquisition +5,277 $68.92
2026-06-21 Fred Hassan Lead Independent Director Other Acquisition +3,990 --
2026-06-21 Fred Hassan Lead Independent Director Other Derivative Acquisition +5,277 $68.92

Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.

Quote time 2026-11-20 20:01:24 · For reference only, not investment advice and not tailored to your situation.

BridgeBio Pharma discussion 0 comments

Add a comment